Company Overview and News
Downtrend: TM shares fell six sen, or 2.34, to close at RM2.50 yesterday. At that price, TM’s market cap stood at RM9.4bil, compared with RM22.69bil at the start of the year. — Bernama
TGLVY 4863 7113 TPGVF MYTEF 5246 GEBHF 7277
KUALA LUMPUR (Oct 18): CIMB IB Research said Telekom Malaysia Bhd could be excluded as a constituent stock while Top Glove Corp Bhd may be added when FTSE Russel announces the outcome of ist semi-annual review of the FBM KLCI constituents on Dec 6 this year.
TGLVY 4863 7113 TPGVF MYTEF 5246 GEBHF 7277
KUALA LUMPUR (Oct 10): Axiata Group Bhd, Telekom Malaysia Bhd (TM) and Genting Bhd were the three biggest laggards among the FBM KLCI component stocks in the afternoon session.
GMALF 5168 6033 7277 CIMDF GMALY 1023 PNADF 4863 5347 4715 TNABY 6888 AXXTF MYTEF TNABF PNAGF GEBHF HRGHY
KUALA LUMPUR (Oct 2): The FBM KLCI rose 5.69 points or 0.32% to its intraday peak on local institutional support as global crude oil prices hit a four-year high.
KUALA LUMPUR (Sept 27): Maybank Investment Bank Bhd is issuing 15 new European style cash-settled call warrants which will be listed tomorrow (Sept 28, 2018), with an issue size of 100 million each.
4634 2852 4863 5148 BRDBF 5263 MYTEF HIPEF 7277 5210 5199
KUALA LUMPUR (Sept 21): The FBM KLCI closed 6.94 points or 0.38% higher, while value across Bursa Malaysia climbed to RM3.61 billion as investors reckoned that the China-US trade war appeared to be less harsh than expected.
1155 1023 MLYBY MLYNF BSMAF MSCI 7277 1818 CIMDF
KUALA LUMPUR (Sept 20): The FBM KLCI pared some of its gains and was up 0.28% at midday break, while remaining above the crucial 1,800-point level, in line with the advance at most regional markets.
HLFBF APEXF 7052 5183 7090 GMALF PECGF 1082 2291 0096 5256 9334 5134 7277 5199 GMALY 5436 4588 3026 4715 5819 2836 HIPEF
After a long holiday break last week, the market was volatile as it sought catalysts. It started with a bearish note as global markets were bearish and ended up higher in a week after markets rebounded strongly. The FBM KLCI closed 0.3% higher at 1,803.76 points in the short trading week but the trading range was between 1,777.45 and 1,822.68 points. There was not much movement this week and yesterday, the index closed at 1,800.
1023 5225 SMEBF 4197 Q0F BSMAF 5168 IHHHF 7277 HRGHY 1818 CIMDF
KUALA LUMPUR (Sept 13): RHB Retail Research said Dialog Group Bhd’s buying momentum may have returned after it rose above the 21-day SMA line.
KUALA LUMPUR (Sept 12): The FBM KLCI dipped 0.55% at midday break today, in line with pull back at most regional markets.
4065 7036 7113 5681 TPGVF 0096 9334 6033 7277 7123 5199 TGLVY 5139 5238 PNADF 3026 0900 2836 HIPEF PNAGF 3719
KUALA LUMPUR (Sept 5): CIMB IB Research said August was a good month for the KLCI as the market ended on a positive note despite disappointing 2Q GDP growth and a soft corporate earnings season but said the stock market could be volatile in the months ahead.
5246 GEBHF 7277
The FBM KLCI snapped a five-week gain last week as the market started to take profit. The index declined 1.2% in a week to 1,783.47 points last Friday, in line with global market performances. However, the index rebounded this week and closed at 1,798.11 points.
4065 MYPRY 5168 5014 7277 HRGHY
KUALA LUMPUR (Aug 17): RHB Research Institute Sdn Bhd and Public Investment Bank Bhd had today raised their target prices (TPs) for Dialog Group Bhd shares to RM4.13 and RM3.73 respectively after Dialog said net profit rose to RM114.85 million in the fourth quarter ended June 30, 2018 (4QFY18) from RM103.55 million a year earlier.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...